摘要
目的 检测肝门部胆管癌新鲜组织中多药耐药基因(mdr-1)mRNA表达,探讨其与肝门部胆管癌临床病理间的关系.方法 应用逆转录聚合酶链反应(RT-PCR)对26例术前未作化疗的肝门部胆管癌和12例正常胆管mdr-1 mRNA进行了检测,并与癌组织的分化程度、病理类型、部位、浸润转移作对比研究.结果 26例肝门部胆管癌组织中mdr-1 mRNA阳性表达率为65.4%(17/26),正常胆管组织表达率为8.3%(1/12),二者差异有显著性(P<0.01).mdr-1 mRNA阳性表达与肝门部胆管癌的分化程度、发生部位、病理类型、浸润转移无关(P>0.05).结论 肝门部胆管癌中有mdr-1 mRNA的高表达,mdr-1阳性可做为肝门部胆管癌化疗耐药的指标.
Objective : To detect the levels of mdr-1 gene expreession in fresh untreated hilar cholangiocarcinoma, and to correlated these levels to current prognostic indicators of clinicopathology. Methods: mdr-1 mRNA expression of 26 cases untreated hilar cholangiocarcinoma and 12 cases normal bile duct tissue was examined with reverse transcriptase-polymerase chain reaction(RT-PCR). Results: mdr-l mRNA Expression in tumor tissue was found in 65.4% (17/26) of patients, whereas, it was seen in normal bile duct 8.3%(1/12) (p<0.01). No correlation with differentiation, invasion, metastasis and Nevin stage, clinical type, pathological type(P>0.05). Conclusion: Higher expression of mdr-1 mRNA in hilar cholangiocarcinoma and mdr-l might serve as indication for drug resistance in chemotherapy.
出处
《中国现代普通外科进展》
CAS
1999年第1期28-30,共3页
Chinese Journal of Current Advances in General Surgery
